As part of PAH Awareness Month this year November 18th has been assigned as the official CTEPH Awareness Day. This will be the first ever awareness day focused on CTEPH or chronic thromboembolic pulmonary hypertension. … [Read more...]
Combination Therapy for PAH: AMBITION Study Yields Impressive Results
Gilead recently presented the results of AMBITION, their largest PAH study. This study compared the long term outcomes of pulmonary arterial hypertension patients who had been recently diagnosed and were randomized to either Tadalafil (Adcirca), Ambrisentan (Letairis) or the combination of the two. … [Read more...]
I Was Misdiagnosed With PAH
We look forward to and read every email readers send us through our contact form. We find the questions and comments submitted to be very valuable and try to respond to each contact. We recently had a reader submit a great question and have written this blog to answer it. … [Read more...]
November is Pulmonary Hypertension Awareness Month
November is the official Pulmonary Hypertension Awareness month. It is important to raise awareness about Pulmonary Hypertension in every community. Heightened awareness leads to better care for PAH patients, increased referrals to pulmonary hypertension specialty centers, decreased time to diagnosis, and increased funds for research for new treatments and potentially a cure. … [Read more...]
Orenitram Now Available To Treat PAH
Orenitram (trepostinil), fondly referred to by some as oral Remodulin, was approved by the FDA to treat PAH in December 2013 and is now available by prescription to the public. … [Read more...]
